在自主性同核蛋白病变中减少尿路内对诺阿基因和多巴胺的分泌
David S Goldstein1, Patti Sullivan2, Courtney Holmes2
1Autonomic Medicine Section (AMS), Clinical Neurosciences Program (CNP), Division of Intramural Research (DIR), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), 10 Center Drive MSC-1620, Building 10 Room 8N260, Bethesda, MD, 20892-1620, USA. goldsteind@ninds.nih.gov.
概括
像帕金森病这样的自主性同核蛋白病变显示尿路的诺亚上腺素和多巴胺分泌量减少. 这表明在这些神经退行性疾病中可能存在功能障碍.
科学领域:
- 神经科学是一个神经科学.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
背景情况:
- 自主性同核蛋白病变,包括帕金森病 (PD),纯自主性衰竭 (PAF) 和多重系统缩 (MSA),以自主性功能障碍和α-synuclein沉积为特征.
- 这些情况涉及儿科胺基异常,但脏儿科胺基功能的理解仍然很差.
研究的目的:
- 通过测量关键类甲醇胺及其代谢物的尿液分泌率,对患有自主性同核蛋白病变的患者的脏类甲醇胺功能进行调查.
- 为了比较患有PD,PAF,MSA和健康对照患者之间的这些排泄率.
主要方法:
- 在NIH临床中心从1995年到2024年收集尿液数据的回顾性审查.
- 在PD,PAF,MSA群体中测量尿道分泌率的北上腺素,上腺素,多巴胺,DOPA,DHPG和DOPAC,以及没有自主功能衰竭或运动障碍的对照队列.
主要成果:
- 与对照人群相比,在PD,PAF和MSA中观察到尿液中尿液排泄率显著降低的诺阿皮内林.
- 在所有三组患者中,多巴胺分泌量也显著降低.
- 在PD和PAF中,DHPG的分泌量下降,但在MSA中没有降低. 在不同组中,DOPA和上腺素的分泌量没有显著差异.
结论:
- 自主性同核蛋白病变与尿路分泌的减少有关. 上腺素和多巴胺.
- 这些发现可能表明交感性诺亚上腺系统,DOPA-多巴胺系统或两者的功能障碍.
- 需要进一步的研究,以阐明这些观察到的 катехоламинергия异常背后的精确机制.
更多相关视频
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Drugs Affecting Neurotransmitter Release or Uptake
947
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
947
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Disorders of the Autonomic Nervous System
561
The autonomic nervous system (ANS) is an intricate network of nerves that controls functions such as the regulation of heart rate, digestion, and blood pressure regulation. When this system malfunctions, it can lead to various disorders that affect multiple bodily functions. One common feature of many autonomic disorders is the involvement of smooth blood vessels, which play a crucial role in regulating blood flow throughout the body.
Raynaud's disease, also known as Raynaud's...
Raynaud's disease, also known as Raynaud's...
561
Parkinson's Disease: Treatment
219
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
219
Parkinson's Disease: Overview
479
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
479


